Peptidyl-prolyl isomerase cyclophilin A (CypA) plays important roles in
inflammation. However, little is known about the mechanisms by which CypA
exerts its effects. It is secreted in human by monocytes activated by high
glucose level. It has a role as an inflammatory mediator in vascular tissue damage.
Aim
This study aims to compare plasma levels of CypA in type 2 diabetic patients with or
without coronary artery disease (CAD) with those in healthy participants to
determine the potential role of CypA in promoting vascular disease in diabetic
patient and to study the association of high-sensitivity C-reactive protein with CypA
levels.
Patients and methods
The present study was conducted on 80 participants who were divided into four
groups: group 1, which included apparently healthy individuals; group 2, which
included patients with type 2 diabetes mellitus (DM) without CAD; group 3, which
included patients with type 2 DM with CAD; and group 4, which included patients
with CAD without DM. The plasma level of CypA was measured using a CypA
enzyme-linked immunosorbent assay kit.
Results
The results showed an increase in the median CypA concentration in all patient
groups in comparison with the controls (P< 0.001). Also, there was a statistically
highly significant increase in the median CypA concentration in diabetic patients
with CAD group when compared with only diabetic patients group (P< 0.001) and
in patient with only CAD when compared with diabetic patients with or without CAD
(P< 0.001).
Conclusion
This study demonstrated that CypA has a potential role in promoting vascular
disease in diabetic patients and revealed that CypA is a good biomarker for CAD
with or without DM better than high-sensitivity C-reactive protein. |
